New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
June 15, 2022 07:30 ET
|
Biogen Inc.
RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA treatment following...
The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
June 14, 2022 07:30 ET
|
Biogen Inc.
The Biogen Foundation has granted $70 million to help underserved communities in advancing science education, health equity, and food securityMore than 61,000 students have benefitted from Biogen’s...
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
June 06, 2022 07:30 ET
|
Biogen Inc.
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s DiseaseAlectos to receive a $15 million upfront payment and is...
Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
June 03, 2022 08:00 ET
|
Biogen Inc.
CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800...
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
June 03, 2022 05:20 ET
|
Biogen Inc.
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained...
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
May 05, 2022 07:30 ET
|
Biogen Inc.
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)MedRhythms to receive a $3 million upfront payment...
New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
April 04, 2022 16:06 ET
|
Biogen Inc.
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm...
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
March 30, 2022 07:30 ET
|
Biogen Inc.
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of...
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
March 28, 2022 07:30 ET
|
Biogen Inc.
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis...
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
March 16, 2022 11:54 ET
|
Biogen Inc.
CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript...